The debate surrounding GLP-1 RA medications is heating up, and it's a controversial topic that affects many. Are these drugs, designed to help manage weight and cardiometabolic risks, becoming lifelong commitments for patients?
A recent study published in the BMJ has sparked discussions about the consequences of discontinuing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and similar therapies. The review revealed that weight often returns swiftly after stopping treatment, sometimes faster than with other weight-loss methods. But it's not just about weight; blood pressure, blood glucose, and blood lipids also revert to pre-treatment levels.
But here's where it gets controversial: Should patients even start these medications? Experts weigh in on the evidence.
Weight Regain: Expected but Not the Core Issue
Professor Clare Collins, an expert in nutrition and dietetics, explains that the rapid weight regain after stopping treatment is not surprising. It aligns with the principle that when an effective treatment is withdrawn, the condition often returns. However, the more significant concern is the deterioration of metabolic markers, which underscores the need for long-term maintenance strategies.
Understanding the Rebound Effect
Associate Professor Trevor Steward clarifies that the rebound effect is not a sign of drug failure but rather how GLP-1 RA medications work. These drugs amplify existing hormonal signals, especially those related to appetite, digestion, and satiety. The rapid weight gain after stopping treatment is due to the absence of these amplified signals.
And this is the part most people miss: The mechanisms behind the accelerated weight regain are still not fully understood, but emerging evidence suggests that incretin therapies may influence the brain's reward pathways, affecting appetite and responses to environmental food cues.
Nutrition: The Missing Piece of the Puzzle
Prof. Collins highlights that dietary changes are often overlooked in incretin trials. Most trials provide standardized advice but don't collect data on dietary intake, making it challenging to understand the long-term impact on eating patterns. Reduced intake doesn't guarantee improved diet quality, and micronutrient deficiencies can emerge without proper monitoring. Pharmacists, with their frequent patient contact, can play a crucial role in identifying these issues and referring patients to dietitians for medical nutrition therapy.
Long-Term Perspective
A/Prof Steward argues that weight regain after stopping treatment is expected, and given the risks of long-term obesity, continued therapy might be a safer option for some. For individuals with repeated weight loss and regain cycles, GLP-1 RAs are increasingly viewed as lifelong treatments, similar to medications for chronic conditions. However, more evidence is needed regarding tapering and maintenance strategies.
A thought-provoking question: As the use of these medications expands, should patients be made aware of the potential long-term commitment and the need for ongoing maintenance strategies? And what role can pharmacists play in educating patients about the seriousness of these medications and their long-term implications?
While the BMJ study doesn't discourage prescribing, Prof. Collins emphasizes the importance of considering costs early on, especially as maintenance strategies evolve. As new formulations and potential PBS listings emerge, clinical messaging will need to adapt to the evolving evidence and the growing number of Australians using these medications.
